After a two-decade cycle of investor embrace and rejection, partnerships won and lost, failed clinical trials, layoffs, and rebuilds, Isis Pharmaceuticals has gained approval for the first ...

A new research paper was published in Volume 17, Issue 12 of Aging-US on December 1, 2025, titled “CD47 antisense ...

Dublin, Oct. 01, 2025 (GLOBE NEWSWIRE) -- The "Antisense Oligonucleotides Market Industry Trends and Global Forecasts to 2035: Distribution by Type of Antisense Molecule, Type of ASO Generation, ...

Frontotemporal dementia (FTD) and amyotrophic lateral sclerosis (ALS) are two fatal neurodegenerative diseases marked by different clinical signs. But they are believed to be caused by a common ...

Stanley T. Crooke, MD, PhD, CEO of Ionis Pharmaceuticals and recipient of the 2016 Lifetime Achievement Award from the Oligonucleotide Therapeutic Society presents a detailed look at the mechanisms ...

Using a short, synthetic chain of chemically modified nucleotides engineered in the RNA Therapeutics Institute at UMass Chan Medical School, Robert H. Brown Jr., DPhil, MD, Jonathan Watts, PhD, and ...

Diffuse intrinsic pontine glioma (DIPG) is a lethal pediatric brain cancer that often kills within a year of diagnosis. DIPG occurs in an area of the brainstem called the pons, which controls many of ...

Biogen is still reeling from the pivotal failure of aducanumab in Alzheimer’s disease, but it is celebrating some positive news from another pipeline asset in neurology. Preliminary results from a ...

Figure 2: Effect of liposomally encapsulated PB2-as on the virus titer in the lungs of mice infected with 100 LD 50 of influenza A virus. Figure 4: Representative photographs showing the effects of ...

Please provide your email address to receive an email when new articles are posted on . CHICAGO — An N-acetyl-galactosamine-conjugated antisense oligonucleotide significantly reduced lipoprotein(a), ...